337 related articles for article (PubMed ID: 367574)
1. Low dose chemotherapy of metastatic breast cancer with cyclophosphamide, adriamycin, methotrexate, 5-fluorouracil (CAMF) versus sequential cyclophosphamide, methotrexate, 5-fluorouracil (CMF) and adriamycin.
Creech RH; Catalano RB; Harris DT; Engstrom PF; Grotzinger PJ
Cancer; 1979 Jan; 43(1):51-9. PubMed ID: 367574
[TBL] [Abstract][Full Text] [Related]
2. Adriamycin versus methotrexate in five-drug combination chemotherapy for advanced breast cancer: a randomized trial.
Muss HB; White DR; Richards F; Cooper MR; Stuart JJ; Jackson DV; Rhyne L; Spurr CL
Cancer; 1978 Nov; 42(5):2141-8. PubMed ID: 363253
[TBL] [Abstract][Full Text] [Related]
3. Prolonged disease-free survival in advanced breast cancer treated with "super-CMF" adriamycin: an alternating regimen employing high-dose methotrexate with citrovorum factor rescue.
Henderson IC; Gelman R; Canellos GP; Frei E
Cancer Treat Rep; 1981; 65 Suppl 1():67-75. PubMed ID: 6976832
[TBL] [Abstract][Full Text] [Related]
4. Mitoxantrone, 5-fluorouracil, and high dose leucovorin (NFL) versus intravenous cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in first-line chemotherapy for patients with metastatic breast carcinoma: a randomized phase II trial.
Hainsworth JD; Jolivet J; Birch R; Hopkins LG; Greco FA
Cancer; 1997 Feb; 79(4):740-8. PubMed ID: 9024712
[TBL] [Abstract][Full Text] [Related]
5. Adriamycin plus vincristine compared to and combined with cyclophosphamide, methotrexate, and 5-fluorouracil for advanced breast cancer.
De Lena M; Brambilla C; Morabito A; Bonadonna G
Cancer; 1975 Apr; 35(4):1108-15. PubMed ID: 1116104
[TBL] [Abstract][Full Text] [Related]
6. Dose-intensive epirubicin-based chemotherapy is superior to an intensive intravenous cyclophosphamide, methotrexate, and fluorouracil regimen in metastatic breast cancer: a randomized multinational study.
Ackland SP; Anton A; Breitbach GP; Colajori E; Tursi JM; Delfino C; Efremidis A; Ezzat A; Fittipaldo A; Kolaric K; Lopez M; Viaro D;
J Clin Oncol; 2001 Feb; 19(4):943-53. PubMed ID: 11181656
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant chemotherapy with doxorubicin plus cyclophosphamide, methotrexate, and fluorouracil in the treatment of resectable breast cancer with more than three positive axillary nodes.
Buzzoni R; Bonadonna G; Valagussa P; Zambetti M
J Clin Oncol; 1991 Dec; 9(12):2134-40. PubMed ID: 1960555
[TBL] [Abstract][Full Text] [Related]
8. A new six-drug antiblastic regimen (R 14) at low doses (micropolychemotherapy) compared to CMF in the treatment of metastatic breast cancer: phase III study.
Pannuti F; Iafelice G; Martoni A; Fruet F; Angelelli B; Casadei M
Chemioterapia; 1984 Aug; 3(4):216-9. PubMed ID: 6398121
[TBL] [Abstract][Full Text] [Related]
9. Doxorubicin versus methotrexate both combined with cyclophosphamide, 5-fluorouracil and tamoxifen in postmenopausal patients with advanced breast cancer--a randomised study with more than 10 years follow-up from the Danish Breast Cancer Cooperative Group. Danish Breast Cancer Cooperative Group (DBCG).
Andersson M; Madsen EL; Overgaard M; Rose C; Dombernowsky P; Mouridsen HT
Eur J Cancer; 1999 Jan; 35(1):39-46. PubMed ID: 10211086
[TBL] [Abstract][Full Text] [Related]
10. Combination chemotherapy of metastatic breast cancer: a randomized trial comparing the use of adriamycin to that of Vinblastine.
Bezwoda WR; de Moor NG; Derman D; Lange M; Saner R; Dando R
Cancer; 1979 Aug; 44(2):392-7. PubMed ID: 383254
[TBL] [Abstract][Full Text] [Related]
11. Cyclophosphamide, methotrexate, and fluorouracil with and without doxorubicin in the adjuvant treatment of resectable breast cancer with one to three positive axillary nodes.
Moliterni A; Bonadonna G; Valagussa P; Ferrari L; Zambetti M
J Clin Oncol; 1991 Jul; 9(7):1124-30. PubMed ID: 2045854
[TBL] [Abstract][Full Text] [Related]
12. Comparison of CMF (cyclophosphamide, methotrexate, and 5-fluorouracil) with a rotational crossing and a sequential intensification regimen in advanced breast cancer: a prospective randomized study.
Cocconi G; Bisagni G; Bella M; Acito L; Anastasi P; Carpi A; Di Costanzo F; Frassoldati A; Mosconi A; Borrini A; Buzzi P
Am J Clin Oncol; 1999 Dec; 22(6):593-600. PubMed ID: 10597744
[TBL] [Abstract][Full Text] [Related]
13. Combination chemotherapy for advanced breast cancer: two regimens containing adriamycin.
Kennealey GT; Boston B; Mitchell MS; Knobf MK; Bobrow SN; Pezzimenti JF; Lawrence R; Bertino JR
Cancer; 1978 Jul; 42(1):27-33. PubMed ID: 667798
[TBL] [Abstract][Full Text] [Related]
14. Combination chemotherapy with cyclophosphamide, adriamycin, intermediate dose methotrexate, and folinic acid rescue (CAMF) in advanced lung cancer.
Robert F; Omura G; Bartolucci AA
Cancer; 1980 Jan; 45(1):1-5. PubMed ID: 6985825
[TBL] [Abstract][Full Text] [Related]
15. Sequential administration of doxorubicin and paclitaxel followed by cyclophosphamide, methotrexate and 5-fluorouracil combination (CMF) in women with metastatic breast cancer.
Papadimitriou CA; Dimopoulos MA; Ampela C; Louvrou-Fertaki A; Anagnostopoulos A; Athanassiades P; Stamatelopoulos S; Keramopoulos A
Oncology; 1998; 55(6):533-7. PubMed ID: 9778619
[TBL] [Abstract][Full Text] [Related]
16. Comparison of induction chemotherapies for metastatic breast cancer. An Eastern Cooperative Oncology Group Trial.
Tormey DC; Gelman R; Band PR; Sears M; Rosenthal SN; DeWys W; Perlia C; Rice MA
Cancer; 1982 Oct; 50(7):1235-44. PubMed ID: 7049347
[TBL] [Abstract][Full Text] [Related]
17. Vincristine, doxorubicin, and cyclophosphamide versus low-dose intravenous cyclophosphamide, methotrexate, and 5-fluorouracil in advanced breast cancer: a randomized trial of the Piedmont Oncology Association.
Muss HB; Richards F; Jackson DV; Cooper MR; White DR; Stuart JJ; Ramseur W; Christian RM; Wells HB; Pope E; Spurr CL
Cancer; 1982 Dec; 50(11):2269-74. PubMed ID: 6754062
[TBL] [Abstract][Full Text] [Related]
18. A randomized comparative trial of adriamycin versus methotrexate in combination drug therapy.
Bull JM; Tormey DC; Li SH; Carbone PP; Falkson G; Blom J; Perlin E; Simon R
Cancer; 1978 May; 41(5):1649-57. PubMed ID: 348293
[TBL] [Abstract][Full Text] [Related]
19. Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen receptor-negative tumors: eight-year results from National Surgical Adjuvant Breast and Bowel Project (NSABP) B-13 and first report of findings from NSABP B-19 comparing methotrexate and fluorouracil with conventional cyclophosphamide, methotrexate, and fluorouracil.
Fisher B; Dignam J; Mamounas EP; Costantino JP; Wickerham DL; Redmond C; Wolmark N; Dimitrov NV; Bowman DM; Glass AG; Atkins JN; Abramson N; Sutherland CM; Aron BS; Margolese RG
J Clin Oncol; 1996 Jul; 14(7):1982-92. PubMed ID: 8683228
[TBL] [Abstract][Full Text] [Related]
20. Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15.
Fisher B; Brown AM; Dimitrov NV; Poisson R; Redmond C; Margolese RG; Bowman D; Wolmark N; Wickerham DL; Kardinal CG
J Clin Oncol; 1990 Sep; 8(9):1483-96. PubMed ID: 2202791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]